REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
24/01/2026
Voltar para busca
Dado oficial do USPTO
VIVAFOLIN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
53
Atualização mais recente
25/01/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5
Data de depósito
07/04/2014
Data de registro
24/01/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/07/2023
Última transação
25/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
701
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
04/02/2016
Primeiro uso no comércio
04/02/2016
Código do desenho
5
Tipo de titular
03
Localização do titular
DENVER, CO
Examinador
KAPLAN, VALERIE ELIZABETH
Unidade examinadora
L70
Localização atual
TMEG LAW OFFICE 107
Descrição da marca
The mark consists of the wording "VIVAFOLIN".
Titulares e representantes
Titulares
VIVAFOLIN NUTRITION & HEALTH US LIMITED
Lianyungang Jinkang Pharmaceutical Technology Co. Ltd
Representantes
Qin Tao
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical preparations for scientific purposesother than for medical or veterinary use; Calcium salts; Chemical preparations and raw materials in the nature of L-5- Methyl tetrahydrofolate for use in the manufacture of pharmaceuticalmedical and nutritional products; Chemicals for use in industry and science; chemicals for use in the pharmaceuticalnutritional and dietary industries
Classe 5
Medicines for human purposesL-5- Methyl tetrahydrofolate for use as a contraceptive; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the respiratory systemgastrointestinal systemendocrine systemcardiovascular systemnervous systemmasculoskeletal systemurinary systemintegumentary system and reproductive system; Pharmaceutical preparations for treatment of blood disease and disorder; dermatologic pharmaceutical preparations; hormone therapy preparations; Pharmaceutical preparations for the treatments of coldscoughs and influenza; Pharmaceutical preparations for ophthalmic use; Pharmaceutical preparations for treating dandrufflaxativesanalgesicscontraceptivesantiseptics; Pharmaceutical preparations for treatment of hypertension; Pharmaceutical preparations for treatment of obesity; Anti allergic pharmaceutical preparations; Pharmaceutical preparations for treatment of gout; Anti-inflammatory pharmaceuticals; Contraceptive preparations; Dietetic foodsfolic acid for the treatment of vitamin deficiency; Dietetic substances adapted for medical usefolic acid for the treatment of vitamin deficiency; Food for babies; Nutritional supplements; Dietary supplement for animals; Antibiotics; Vitamin preparations; Drugs for medical purposes for the treatment of subacute encephali associated with dementia and vacuolar myelopathyphysiological and pathological vascular and cardiovascular disorders such as premature occlusive arterial diseasessevere vascular diseases in infancy and childhoodprogressive arterial stenosisintermittent claudicationrenal vascular hypertensionischemic cerebrovascular diseasespremature occlusive retinal artery and retinal veincrebral occlusive arterial diseasesocclusive peripheral arterial diseasespremature death caused by thromboembolic diseases and/or ischemic heart diseasesautoimmune diseases such as psoriasisceliac diseasearthritis and inflammatory conditionsmegaloblastic anemia caused by folate inficiencyintestinal malabsorptionused as antidote for folic acid antagonistsused for preventing serious toxic effects caused by methotrexate overdose or high-dose therapyreducing risks of woman miscarriage and/or production of fetuses with neural tube defectscleft lip and/or palate defectskeeping and/or normalizing homocysteine levels and/or metabolismchanges synthesis of and/or functions and/or variations in DNA and RNA and changes in synthesis of cells and depression
Publicações
Histórico de despachos e eventos da marca no USPTO.
53 publicações encontradas
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
12/07/2023
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
12/07/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/07/2023
ES8R
TEAS SECTION 8 RECEIVED
19/01/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
24/01/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
15/07/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/05/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/05/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/05/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/05/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/05/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
24/01/2017
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
21/12/2016
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
20/12/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/12/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/12/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/11/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/11/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
25/07/2016
GNRT
NON-FINAL ACTION E-MAILED
25/07/2016
CNRT
SU - NON-FINAL ACTION - WRITTEN
25/07/2016
DOCK
ASSIGNED TO EXAMINER
03/06/2016
SUPC
STATEMENT OF USE PROCESSING COMPLETE
17/05/2016
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/05/2016
IUAF
USE AMENDMENT FILED
13/04/2016
EISU
TEAS STATEMENT OF USE RECEIVED
13/04/2016
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
20/10/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/08/2015
PUBO
PUBLISHED FOR OPPOSITION
25/08/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/08/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
18/07/2015
ALIE
ASSIGNED TO LIE
18/07/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/07/2015
XAEC
EXAMINER'S AMENDMENT ENTERED
02/07/2015
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/07/2015
GNEA
EXAMINERS AMENDMENT E-MAILED
02/07/2015
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/07/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/06/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/06/2015
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/06/2015
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/01/2015
GNFR
FINAL REFUSAL E-MAILED
05/01/2015
CNFR
FINAL REFUSAL WRITTEN
05/01/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/12/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/12/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/12/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
16/07/2014
GNRT
NON-FINAL ACTION E-MAILED
16/07/2014
CNRT
NON-FINAL ACTION WRITTEN
16/07/2014
DOCK
ASSIGNED TO EXAMINER
14/07/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/04/2014
NWAP
NEW APPLICATION ENTERED
10/04/2014
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VIVAFOLIN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.